JP2020533415A - ナルコレプシーの処置におけるガボキサドールの使用 - Google Patents

ナルコレプシーの処置におけるガボキサドールの使用 Download PDF

Info

Publication number
JP2020533415A
JP2020533415A JP2020536720A JP2020536720A JP2020533415A JP 2020533415 A JP2020533415 A JP 2020533415A JP 2020536720 A JP2020536720 A JP 2020536720A JP 2020536720 A JP2020536720 A JP 2020536720A JP 2020533415 A JP2020533415 A JP 2020533415A
Authority
JP
Japan
Prior art keywords
hours
certain embodiments
patient
pharmaceutically acceptable
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020536720A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020533415A5 (enExample
Inventor
マシュー・デューリング
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ovid Therapeutics Inc
Original Assignee
Ovid Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ovid Therapeutics Inc filed Critical Ovid Therapeutics Inc
Publication of JP2020533415A publication Critical patent/JP2020533415A/ja
Publication of JP2020533415A5 publication Critical patent/JP2020533415A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pyrane Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2020536720A 2017-09-12 2018-09-11 ナルコレプシーの処置におけるガボキサドールの使用 Pending JP2020533415A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762557412P 2017-09-12 2017-09-12
US62/557,412 2017-09-12
PCT/US2018/050339 WO2019055369A1 (en) 2017-09-12 2018-09-11 USE OF GABOXADOL IN THE TREATMENT OF NARCOLEPSIA

Publications (2)

Publication Number Publication Date
JP2020533415A true JP2020533415A (ja) 2020-11-19
JP2020533415A5 JP2020533415A5 (enExample) 2021-10-21

Family

ID=65630168

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020536720A Pending JP2020533415A (ja) 2017-09-12 2018-09-11 ナルコレプシーの処置におけるガボキサドールの使用

Country Status (10)

Country Link
US (2) US20190076409A1 (enExample)
EP (1) EP3661507A4 (enExample)
JP (1) JP2020533415A (enExample)
KR (1) KR20200053570A (enExample)
CN (1) CN111328282A (enExample)
AU (1) AU2018331326A1 (enExample)
CA (1) CA3075478A1 (enExample)
IL (1) IL272962A (enExample)
MX (1) MX2020002741A (enExample)
WO (1) WO2019055369A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3661507A4 (en) * 2017-09-12 2020-11-18 Ovid Therapeutics Inc. USE OF GABOXADOL TO TREAT NARCOLEPSIA
MX2021005992A (es) 2018-11-21 2021-09-14 Certego Therapeutics Inc Gaboxadol para reducir el riesgo de suicidio y para alivio rápido de la depresión.
MX2021016006A (es) 2019-06-28 2022-04-07 Univ Copenhagen Tratamiento de trastornos del sistema nervioso central (snc) con perturbaciones del sueño.
IL298334A (en) 2020-05-20 2023-01-01 Certego Therapeutics Inc Ring deuterated gaboxadol and its use for the treatment of psychiatric disorders
US20250375429A1 (en) 2024-05-29 2025-12-11 Smarter Not Harder, Inc. Obligate pairing of orthosteric and non-orthosteric gaba ligands in pharmaceutical formulations

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007515415A (ja) * 2003-12-18 2007-06-14 ハー・ルンドベック・アクチエゼルスカベット 不眠症の治療にガボクサドールを使用する方法
JP2016512531A (ja) * 2013-03-13 2016-04-28 エアリアル，バイオファーマ，エルエルシー カタプレキシーの治療

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050215521A1 (en) * 2003-12-22 2005-09-29 Karim Lalji Modafinil combination therapy for improving sleep quality
US9480695B2 (en) * 2011-09-29 2016-11-01 The University Of Tokyo Methods for inducing orexin neurons and agent for treating narcolepsy or eating disorder
US9050302B2 (en) * 2013-03-01 2015-06-09 Jazz Pharmaceuticals Ireland Limited Method of administration of gamma hydroxybutyrate with monocarboxylate transporters
US9682069B2 (en) * 2015-07-17 2017-06-20 Ovid Therapeutics Inc Methods of treating Dravet syndrome
WO2017205606A1 (en) * 2016-05-26 2017-11-30 Ovid Therapeutics Inc. Methods of treating behavioral syndromes using pipradrol
EP3661507A4 (en) * 2017-09-12 2020-11-18 Ovid Therapeutics Inc. USE OF GABOXADOL TO TREAT NARCOLEPSIA

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007515415A (ja) * 2003-12-18 2007-06-14 ハー・ルンドベック・アクチエゼルスカベット 不眠症の治療にガボクサドールを使用する方法
JP2016512531A (ja) * 2013-03-13 2016-04-28 エアリアル，バイオファーマ，エルエルシー カタプレキシーの治療

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
DAUVILLIERS, Y. ET AL: "Narcolepsy with cataplexy", LANCET, vol. 369, JPN6022028813, 2007, pages 499 - 511, ISSN: 0005006424 *
MIGNOT, E. ET AL: "Emerging Therapies in Narcolepsy-Cataplexy", SLEEP, vol. 28, no. 6, JPN6022028815, 2005, pages 754 - 763, ISSN: 0005006425 *
WALSH, J. K. ET AL: "Slow Wave Sleep Enhancement with Gaboxadol Reduces Daytime Sleepiness During Sleep Restriction", SLEEP, vol. 31, no. 5, JPN6022028816, 2008, pages 659 - 672, ISSN: 0005006426 *
ZEITZER, J. M. ET AL: "The neurobiology of hypocretins(orexins), narcolepsy and related therapeutic interventions", TRENDS IN PHARMACOLOGICAL SCIENCES, vol. 27, no. 7, JPN6022028812, 2006, pages 368 - 374, ISSN: 0005006423 *

Also Published As

Publication number Publication date
US20190076409A1 (en) 2019-03-14
EP3661507A4 (en) 2020-11-18
MX2020002741A (es) 2020-07-21
AU2018331326A1 (en) 2020-03-19
IL272962A (en) 2020-04-30
EP3661507A1 (en) 2020-06-10
WO2019055369A1 (en) 2019-03-21
US20200222372A1 (en) 2020-07-16
CA3075478A1 (en) 2019-03-21
KR20200053570A (ko) 2020-05-18
CN111328282A (zh) 2020-06-23

Similar Documents

Publication Publication Date Title
EP2688557B1 (en) Methods and compositions for treatment of attention deficit disorder
US10881618B2 (en) Compositions for treatment of attention deficit hyperactivity disorder
JP2020533415A (ja) ナルコレプシーの処置におけるガボキサドールの使用
JP2019116494A (ja) アカンプロサート製剤、それを用いる方法、およびそれを含む合剤
US9283214B2 (en) Compositions for treatment of attention deficit hyperactivity disorder
US9603809B2 (en) Methods of treatment of attention deficit hyperactivity disorder
TWI344840B (en) Modafinil modified release pharmaceutical compositions
US10292937B2 (en) Methods of treatment of attention deficit hyperactivity disorder
CA3040027C (en) Melatonin mini-tablets and method of manufacturing the same
US12383506B2 (en) Compositions for treatment of attention deficit hyperactivity disorder
US10905652B2 (en) Compositions for treatment of attention deficit hyperactivity disorder
US20080058345A1 (en) Combination Therapy with Mecamylamine for the Treatment of Mood Disorders
HK40031715A (en) Use of gaboxadol in the treatment of narcolepsy

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210908

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210908

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220712

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20220715

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20221007

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221209

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20230307